Guess which company just became the first ASX cannabis share to pay a dividend

We take a a look at why this ASX cannabis share is having such a good day.

| More on:
A man in a horse head mask and suit jumps for joy on a beach.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • This ASX cannabis share is declaring a dividend for the first time 
  • The company reported a 324% boost in net profit after tax 
  • This medicinal cannabis company has soared more than 200% in a year 

The Cronos Australia Ltd (ASX: CAU) share price is lifting today amid the company's FY22 results.

Cronos shares are currently trading at 36 cents, a 4.35% lift. In contrast, the S&P/ASX 200 Index (ASX: XJO) is falling 1.94% today.

Let's take a look at what this ASX cannabis share reported today.

Net profit surges by 324%

Highlights of Cronos Australia's FY22 results include:

What else did the company report?

Cronos reported average gross margins between 35% to 40% on its products.

Receipts from customers lifted 245% on the previous year, while net cash flows from operations soared 1,164% to more than $13.5 million.

Cronos said it is the only ASX medicinal cannabis company to declare a dividend. The company is also inviting shareholders to take part in a dividend reinvestment plan.

Cronos now has $16.1 million cash at the bank and no debt aside from standard leases.

The company's medicinal cannabis patients have lifted from nearly zero in 2018 to 100,000 in 2022.

The dividend will be paid on 11 October.

Management commentary

Commenting on the results and dividend, executive director Rodney Cocks said:

Cronos Australia is very pleased to be able to declare a dividend to its shareholders at 1.0 cent
per share, fully franked.

This is, yet again, another first for Cronos Australia, being the first ASX-listed medicinal cannabis company to report a profit and now, the first to declare a dividend.

The Company has achieved record growth during the 2022 financial year and it is
gratifying that the Company can share its success with its shareholders in a very tangible way.

What's next?

This ASX cannabis share is predicting revenue in FY21 to be more than $100 million, based on current sales and growth.

Cronos said the Australian medicinal cannabis market is expected to be more than $400m by the end of the 2022 calendar year, nearly 74% higher than the 2021 calendar year.

Cronos believes it is well positioned for "sustainable, scalable growth" in FY23 and the years ahead.

Cronos share price snapshot

The Cronos Australia share price has soared 227% in a year, while it has climbed 80% year to date.

In the past month alone, this ASX cannabis share has lifted 24%.

For perspective, the benchmark ASX 200 Index has lost nearly 7% in the past year.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A group of business people in a board room hear the latest company report
Earnings Results

Key takeouts for ASX shares this earnings season: CBA analysis

Profits were weaker but plenty of dividends were splashed about this earnings season.

Read more »

Hand of a woman carrying a bag of money, representing the concept of saving money or earning dividends.
Earnings Results

Which ASX shares delivered the biggest profit jumps of the earnings season?

These companies revealed at least a 70% profit boost in their latest earnings reports.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Earnings Results

Why this ASX 300 share is leaping 14% despite being branded a 'sell'

Falling profits are putting investors off the fund manager.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Technology Shares

Life360 share price rockets 24% after smashing FY23 earnings expectations

This tech stock delivered a very strong result this morning. How strong was it?

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Earnings Results

What's with the Neuren Pharmaceuticals share price today?

The full market reaction to the Daybue developer's FY23 earnings report won't be seen until tomorrow.

Read more »

Two workers at an oil rig discuss operations.
Earnings Results

2 ASX energy shares going gangbusters on today's earnings results

The ASX energy shares are drawing investor interest today after releasing their half-year earnings results.

Read more »

Man pointing at a blue rising share price graph.
Earnings Results

This ASX 300 stock just jumped 12%! Here's why

The ASX 300 stock is impressing investors with its half-year earnings results.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Mesoblast share price tumbles on US$32.5m half-year loss

This biotech continues to burn cash.

Read more »